Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05823974 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,275
- Enrollment target
NCT05823974 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,275 participants.
The verdict
NCT05823974, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,275 participants
- Enrollment target
Study Summary
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
Interventions
- BIOLOGICAL F2C22C/DL001Z
- BIOLOGICAL F2B22A/DL001Z
- BIOLOGICAL F2B22B/DL001Z
- BIOLOGICAL F2B22C/DL001Z
- BIOLOGICAL F2B22D/DL001Z
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,275 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05823974
The ClinicalTrials.gov registry entry for NCT05823974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which F2C22C/DL001Z is the first listed.
NCT05823974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05823974 about?
NCT05823974 is a clinical study titled "A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults". The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
What is the current status of trial NCT05823974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,275 participants. The study started on 2023-04-27. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT05823974?
The interventions under investigation include: F2C22C/DL001Z (BIOLOGICAL), F2B22A/DL001Z (BIOLOGICAL), F2B22B/DL001Z (BIOLOGICAL), F2B22C/DL001Z (BIOLOGICAL), F2B22D/DL001Z (BIOLOGICAL).
Who is sponsoring clinical trial NCT05823974?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.